420 Real Properties: Los Angeles Arts District 10K SQFT in Los Angeles at $2 PSF | CashCropToday
0 Shares 52 Views

420 Real Properties: Los Angeles Arts District 10K SQFT in Los Angeles at $2 PSF

October 5, 2018
52 Views

732 Ceres Ave. Los Angeles CA 90021

This property is ready and waiting for you to move in and plan the buildout of your dreams. It’s walking distance to the LA arts district and is zoned M2, making it perfect for:

– Retail Storefront

– Indoor Cultivation

– Microbusiness

– Manufacturing Levels 1 and 2

– Delivery

– & Testing 

And, with 600 AMPS of 3-phase power, 12′ ceilings, 2 floors at 5,000 SQFT each, a small section of office space, two roll-ups, up to 9 parking spaces, and a private, gated entrance, there’s a lot to love.

Call or email us at 949-916-0022 x407 or info@420realproperties.com today to schedule a complimentary consultation and make this space yours.

420 Real Properties – Paul K. Thompson – CAL BRE # 00547210

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
274 views
Market Watch
274 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
195 views
Global
195 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
191 views
Manufacturing
191 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: